US FDA Approved BeiGene’s BRUKINSA to Treat Chronic Lymphocytic Leukemia

The global biotechnology company BeiGene announced that the Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with CLL or SLL has received approval from the U.S. Food and Drug Administration (FDA). Mehrdad Mobasher, Chief Medical Officer, Hematology at BeiGene, said that they believe BRUKINSA is well-positioned to become the BTKi […]

Continue Reading

US FDA Announced, Blood Pressure Medicine Recalled Due to Potential Cancer Risk

The US Food and Drug Administration (FDA), announced that the pharmaceutical company Aurobindo Pharma is recalling a blood pressure medication because of a potential cancer risk. The company is recalling two lots of quinapril and hydrochlorothiazide tablets because of the levels of nitrosamine. The tablets are most commonly prescribed for the treatment of hypertension to […]

Continue Reading

US FDA Grants Moleculin Orphan Drug Designation of WP1122 to Treat Glioblastoma Multiforme

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation of WP1122 to Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, for the treatment of Glioblastoma Multiforme (GBM). Walter Klemp, chairman and CEO of Moleculin Biotech, Inc., said the receipt of Orphan Drug Designation is represents an important milestone for their promising WP1122 development […]

Continue Reading

AstraZeneca Enhertu Secures US FDA Approval for HER2-Low Breast Cancer

The US Food and Drug Administration (FDA) has approved Enhertu of AstraZeneca and Daiichi Sankyo for the treatment of adult patients with metastatic HER2-low breast cancer, who have received a prior chemotherapy in the metastatic setting during six months of completing adjuvant chemotherapy. Enhertu is a specifically designed HER2-directed antibody drug conjugate (ADC), that has […]

Continue Reading